A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer.

Moiola CP, Lopez-Gil C, Rebull M, Sotoca A, De la Calle I, García Á, Denizli M, Salazar L, van der Vleuten M, Bebia V, Tubita V, Groothuis P, Gil-Moreno A, Colas E

Open source

DOI: 10.1016/j.biopha.2026.119830
Published: 2026 Sep
Container: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.biopha.2026.119830,
  title = {A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer.},
  author = {Moiola CP and Lopez-Gil C and Rebull M and Sotoca A and De la Calle I and García Á and Denizli M and Salazar L and van der Vleuten M and Bebia V and Tubita V and Groothuis P and Gil-Moreno A and Colas E},
  year = {2026},
  journal = {Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  doi = {10.1016/j.biopha.2026.119830},
  url = {https://doi.org/10.1016/j.biopha.2026.119830}
}

RIS

TY  - JOUR
TI  - A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer.
AU  - Moiola CP
AU  - Lopez-Gil C
AU  - Rebull M
AU  - Sotoca A
AU  - De la Calle I
AU  - García Á
AU  - Denizli M
AU  - Salazar L
AU  - van der Vleuten M
AU  - Bebia V
AU  - Tubita V
AU  - Groothuis P
AU  - Gil-Moreno A
AU  - Colas E
PY  - 2026
JO  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
DO  - 10.1016/j.biopha.2026.119830
UR  - https://doi.org/10.1016/j.biopha.2026.119830
ER  -

APA

CP, M., C, L., M, R., A, S., I, D. L. C., Á, G., M, D., L, S., M, V. D. V., V, B., V, T., P, G., A, G., & E, C. (2026). A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2026.119830

Source records

pubmed · retrieved 2026-09-27T06:45:16.005Z